Lantern Pharma to Showcase at ThinkEquity Conference in New York City on October 30, 2025
Company Presentation: Lantern Pharma Inc. will present at the ThinkEquity Conference on October 30, 2025, at 11:30 a.m. ET in New York, NY, with opportunities for one-on-one meetings available throughout the event.
AI-Driven Drug Development: The company utilizes its proprietary AI platform, RADR®, to enhance oncology drug discovery and development, aiming to address significant challenges in the field and potentially impacting over $15 billion in market potential.
Clinical Programs: Lantern Pharma is advancing multiple clinical programs, including a Phase 2 program and several Phase 1 trials, targeting various cancer types with the goal of providing innovative therapies to patients.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future performance and drug development plans, highlighting potential risks and uncertainties that could affect outcomes.
Get Free Real-Time Notifications for Any Stock
Analyst Views on LTRN
About LTRN
About the author
New to The Street Highlights Blockchain and Oncology Innovations in Episode #710
- Blockchain Infrastructure Acceleration: TokenFI's Chief Revenue Officer Pedro Vidal discussed strategies for accelerating institutional adoption of blockchain tokenization, aiming to build scalable, compliance-ready infrastructure for real asset issuance, which is expected to drive transformation in financial markets.
- New Oncology Treatment Platform: NeOnc Technologies' CEO Amir Heshmatpour introduced an intranasal drug delivery platform targeting aggressive brain cancers along with its clinical and regulatory roadmap, potentially providing new treatment options and improving survival rates for patients.
- AI-Driven Drug Discovery: Lantern Pharma's CEO Panna Sharma outlined their AI-driven approach to oncology drug discovery, enhancing research speed and capital efficiency, which is anticipated to increase clinical success rates and expedite new drug market entry.
- Infrastructure Investment Strategy: Mataterra Holdings' co-chairmen Monika Proffitt and Douglas Anderson provided strategic insights on global infrastructure development and real asset tokenization, emphasizing the importance of capital formation to meet future market demands.
Lantern Pharma Announces Encouraging Phase 1a Results for LP-184 in Advanced Solid Tumors
Clinical Study Results: Lantern Pharma's Phase 1a dose-escalation study of LP-184 demonstrated promising disease control in patients with advanced solid tumors and DNA damage repair deficiencies, meeting all safety and tolerability endpoints.
Future Plans: The company intends to progress LP-184 into multiple Phase 1b/2 trials following the successful outcomes of the initial study.
